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Abstract
Dupuytren’s disease is a common fibrotic condition of the hand affecting
4% of the population and causes the fingers to curl irreversibly into the
palm. It has a strong familial tendency, there is no approved treatment for
early stage disease, and patients with established digital contractures are
most commonly treated by surgery. This is associated with prolonged
recovery, and less invasive techniques have high recurrence rates.The
myofibroblasts, the cells responsible for the excessive matrix deposition
and contraction, are aggregated in nodules. Using excised diseased and
control human tissue, we found that immune cells interspersed amongst the
myofibroblasts secrete cytokines. Of these, only tumour necrosis factor
(TNF) promoted the development of myofibroblasts. The clinically approved
anti-TNF agents led to inhibition of the myofibroblast phenotype  .in vitro
This clinical trial is designed to assess the efficacy of the anti-TNF agent
adalimumab on participants with early disease. The first part is a
dose-ranging study where nodules of participants already scheduled for
surgery will be injected with either placebo (saline) or varying doses of
adalimumab. The excised tissue will then be analysed for markers of
myofibroblast activity.The second part of the study will recruit participants
with early stage disease. They will be randomised 1: 1 to receive either
adalimumab or placebo at 3 month intervals over 1 year and will then be
followed for a further 6 months. Outcome measures will include nodule
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 followed for a further 6 months. Outcome measures will include nodule
hardness, size and disease progression. The trial will also determine the
cost-effectiveness of adalimumb treatment for this group of participants.
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Introduction
Background
Dupuytren’s disease (DD) is extremely common and is estimated 
to affect approximately 4% of the general UK and US populations1. 
Between 35–50% of patients with early DD manifest as nod-
ules on the palmar aspect of the hand go on to develop finger 
contractures2,3. The nodules are typically quiescent for a period 
and then become active, progressing to flexion deformities over 
a period of months4. The mainstay of treatment remains surgical 
excision (fasciectomy) of the diseased tissue or cords5, and recent 
US data show that ~60% of treated patients undergo surgery, 
with the remainder equally split between collagenase and needle 
fasciotomy. Generally, patients are offered these treatments 
once digits are flexed to 30 degrees or more and hand function is 
impaired6. The recurrence rate in patients treated with surgery is 
10–12% within 3 years7, and these individuals may require more 
extensive surgery involving excision of the diseased tissue and 
overlying skin (dermofasciectomy). Post-operatively, patients 
require 3–6 months of hand therapy and splintage8. Complica-
tions occur in approximately 20% of patients undergoing surgery 
for DD9,10. Alternative, less invasive techniques to disrupt the cords 
of diseased tissue with either a needle11 or collagenase digestion12 
are associated with rapid recovery of hand function with minimal 
therapy13. However, recurrence rates are high, affecting 70% of 
patients treated with percutaneous needle aponeurotomy7 and 
35% of those treated with collagenase14 at 3 years. The compli-
cation rate is 20% following needle aponeurotomy10 and over 
70% after collagenase injection15.
There is currently no approved therapy for the treatment of early 
DD. An uncontrolled and unblinded retrospective review of int-
ralesional steroid injection at 6 week intervals in 63 patients with 
early DD reported that following a mean of 3.2 injections, there 
was subjective improvement of 60–80% in 97% of patients and dis-
ease reactivation occurred in 50% of patients 1 to 3 years after the 
last injection16. Given the paucity and quality of data, this treatment 
modality has found limited acceptance. Similarly, studies report-
ing the efficacy of radiotherapy are limited by a lack of quality, 
with no blinding or randomisation and the use of subjective out-
come measures. A recent systematic review of studies reporting 
outcomes in patients with early disease treated with radiotherapy17 
found that in four studies participant numbers were small (10 or 
fewer)18–21. Of the remaining 6 studies, 2 reported improvement22,23, 
3 described equivocal results24–26 and one showed no change27. 
One study noted that results following radiotherapy did not dif-
fer from the natural history of early DD26. Approximately 20–30% 
of patients receiving radiotherapy in the studies included in the 
systematic review developed long term adverse effects, including 
dry skin, desquamation, skin atrophy, telangiectasia, erythema, and 
altered heat and pain sensation20–22,24–26. Based on the published 
data, NICE recommends that radiotherapy should only be used with 
special arrangements for clinical governance, consent and audit or 
in a research setting28.
Therefore, there is a need to develop an effective therapy to retard 
progression of early DD and also prevent the development of 
recurrent disease following surgery, needle fasciotomy or colla-
genase injection in patients with established finger contractures.
Our laboratory studies based on tissues from patients with DD 
normally discarded at the time of surgery revealed the presence 
of innate immune cells, including macrophages, clustered in 
nodules29. Freshly disaggregated cells from the nodules secreted a 
range of cytokines. The effects of these cytokines on contraction 
and profibrotic signaling pathways were assessed in fibroblasts from 
the palmar and non-palmar dermis of Dupuytren’s patients, and 
palmar fibroblasts from individuals without Dupuytren’s disease. 
Exogenous addition of TNF, but not other cytokines, including 
IL-6 and IL-1β, promoted differentiation only of palmar dermal 
fibroblasts from patients with Dupuytren’s disease into myofibrob-
lasts via the Wnt signaling pathway. Neutralizing antibodies to 
TNF inhibited the contractile activity of myofibroblasts derived 
from Dupuytren’s patients, reduced their expression of α-smooth 
muscle actin, and mediated disassembly of the contractile appara-
tus. Of the anti-TNF agents approved for clinical use via subcu-
taneous administration, adalimumab and golimumab were found 
to be the most efficacious in downregulating the myofibroblast 
phenotype in vitro at the doses tested29.
Based on these laboratory data, we are proceeding with a phase 
II clinical trial using adalimumab to assess the efficacy of intran-
odular injection for participants with early DD. Adalimumab is 
used to treat other conditions such as inflammatory arthritis and 
inflammatory bowel disease and has a well described safety pro-
file. Our end user survey of 33 patients affected with DD (Table 1) 
indicated that both early disease and established disease patients 
would accept injection therapy that reduced need for future 
surgery.
Table 1. Summary of responses to questionnaire regarding acceptability of injection 
therapy that would retard the progression of disease. The survey was completed by 33 
patients.
Extremely or very 
likely accept:
Patients with 
early Dupuytren’s 
disease (n=15)
Patients who had previously 
undergone surgery for 
Dupuytren’s disease (n=18)
Both cohorts 
combined (n=33)
1 injection per year 
for lifetime
14 (93%) 17 (94%) 31 (94%)
3 injections per 
year for lifetime
9 (60%) 12 (67%) 21 (64%)
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Objectives
The research hypothesis is to determine whether adalimumab 
injections control the progression of early Dupuytren’s disease 
more than placebo (saline). A two part trial has been designed to 
address these objectives.
Study protocol
The two part trial comprises:
1.   Tissue response RCT: A single centre double blind ran-
domised placebo-controlled trial (RCT) to determine the 
response of DD nodular tissue at the molecular level to esca-
lating doses of adalimumab (anti-TNF) injected into the dis-
eased tissue two weeks before planned surgical excision in 
participants with established DD (Figure 1).
2.   Early DD RCT: A multi-centre, double blind, randomised, 
placebo-controlled, parallel group, phase II RCT to deter-
mine the efficacy of intra-nodular injection of anti-TNF in 
controlling disease progression in participants with early 
DD (Figure 2).
1. Tissue response RCT
Study setting: St John’s Hospital NHS Lothian
Participants: Participants with established DD leading to 
contractures ≥30° at either the metacarpophalangeal joint or the 
proximal interphalangeal joint and awaiting scheduled surgery of 
the hand for excision of the diseased Dupuytren’s tissue will be 
invited to join the study. Flexion deformities of ≥30° are associ-
ated with impairment of function and form the criteria used by 
the clinical commissioning groups for surgical referral. The 
diagnosis of DD is made on the basis of the history and clinical 
examination. Only a single nodule will be injected in each par-
ticipant and the most prominent nodule due to be excised will be 
selected.
Intervention: Adalimumab delivered by intra-nodular injection 
12–18 days prior to surgery in one of up to four different doses: 
15mg in 0.3ml carrier, 35mg in 0.7ml carrier, 40mg in 0.4ml 
carrier (new carrier formulation) and a maximum of 80mg in a 
maximum of 0.8ml. A minimum of 8 participants will be recruited 
to each cohort, with up to a maximum of 40 participants in total. 
The last cohort will only be utilised if approved by the Trial 
Steering Committee (TSC) after a blinded interim analysis of the 
laboratory results.
Control: Injection of saline (placebo) of equivalent volume to 
intervention for each cohort.
Outcomes: Please see Table 2.
Figure 1. Flow chart: Tissue response RCT.
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Figure 2. Flow chart: Early disease RCT.
Table 2. Table of Tissue response RCT objectives and outcome measures.
Objectives Outcome measures
Primary 
Objective
1. To establish an effective dose of 
adalimumab for downregulating the 
myofibroblast phenotype 
1. Expression of mRNA for α-SMA.
Secondary 
Objectives
2. To determine the effectiveness of 
adalimumab for myofibroblast inhibition.
2.1. Expression of mRNA for COL-1A1, COL-3A1 and 
cadherin 11. 
2.2. Levels of α-SMA protein. 
2.3. Hardness of selected nodule. 
2.4. Ultrasound imaging of nodule size. 
2.5. Adverse event assessment comparing active and 
placebo groups using visual inspection of injection 
site, surgery site and laboratory reports.
Tertiary 
Objectives
3. Determine circulating levels of adalimumab 
and antibodies to adalimumab in the blood. 
4. To assess if DD injection therapy would be 
acceptable to participants 
5. To evaluate the health-related quality of life 
of participants
3. Analysis of blood sample. 
 
4. Analysis of injection experience questionnaire 
 
5. Analysis of EQ-5D-5L data to estimate utilities using 
quality-adjusted life years (QALYs).
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Primary outcome: Expression of mRNA for α-SMA to establish 
an effective dose of adalimumab for downregulation of the myofi-
broblast phenotype. 
Secondary outcomes: Expression of mRNA for COL-1A1, COL-
3A1 and cadherin 11, and levels of α-SMA protein to determine the 
effectiveness of adalimumab for myofibroblast inhibition. Nodule 
hardness and ultrasound image of nodule dimensions/size. Adverse 
event assessment using visual inspection of injection site, surgery 
site and laboratory reports.
Tertiary outcomes: Circulating levels of adalimumab and antibod-
ies to adalimumab. The injection experience will be rated by the 
participant and the injection site assessed for local adverse events.
Data collection/follow-up summary: Please see Table 3.
Sample size: Up to forty participants, with a minimum of 8 per 
cohort. Numbers are based on in vitro findings for the primary 
outcome measure, α-SMA expression of 0.55±0.11 on treatment 
with anti-TNF, compared to control gene expression of 1.03±0.18 
in controls29.
Recruitment: Participants with established DD and who are due 
to be scheduled for surgery for this disease will be identified and 
approached by hand specialists who will be assessing patients in 
an out-patient clinic. Potential participants will be given the rel-
evant Participant Information Leaflet (PIL) containing a telephone 
number and an e-mail address to request further information.
Randomisation: 3:1 to adalimumab or placebo in each of the dose 
levels. Randomisation is computer-generated by the trial statistician. 
An allocation log will be stored securely in the pharmacy to indi-
cate, for each trial ID, which investigational medicinal product 
(IMP) (drug or placebo) to dispense. Once consent is confirmed 
together with the dose cohort, the pharmacist dispenses the relevant 
treatment. The RRAMP system, an online system run by Oxford 
Clinical Trials Research Unit (OCTRU), will be used to store treat-
ment allocations to enable emergency unblinding. 
Blinding: Participants and healthcare professionals involved in 
follow-up. Healthcare professional delivering injection also blind 
where possible (depending on formulation of adalimumab), as the 
40mg in 0.4ml preparation of adalimumab is only available in a 
pre-filled syringe.
2. Early Dupuytren’s disease RCT
Setting: Multicentre; anticipated to run in three centres including 
Oxford NHS Hospitals Trust.
Participants: Participants with early DD nodules who also 
have shown or report progression of the disease in the previous 
3–6 months will be invited to join the study. Only participants with 
flexion deformities of ≤30° at the metacarpophalangeal and/or at 
the proximal interphalangeal joint will be recruited, so total flexion 
deformity could be up to 60°. The participants will be randomised 
(1:1) to receive injections of either adalimumab or saline into the 
active nodule.
Intervention: Adalimumab 40mg in 0.4ml injected into the nodule 
at baseline, 3, 6 and 9 months after randomisation.
Control: Injection of saline (placebo) of equivalent volume.
Outcomes: Please see Table 4.
Table 3. Summary of schedule for Tissue response RCT.
What will happen? Is this visit combined with 
usual hospital treatment?
Medical check-up 
Approx. 1–2 hours.
Eligibility assessment including chest X-ray and 
blood tests.
Yes, combined with  
pre-operation assessment
Injection visit 
Approx. 2 hours.
       •  Dupuytren’s assessment 
       •  Blood test 
       •  Ultrasound scan 
       •  Hand photo 
       •  EQ-5D-5L Questionnaire 
       •  Nodule hardness 
       •  Injection and then assessment of injection site
No
Surgery day 
Approx. 1 hour.
       •  Assessment of injection site 
       •  Blood test 
       •  Ultrasound scan 
       •  Hand photo 
       •  Nodule hardness
Yes, while waiting for 
surgery
2 weeks after 
surgery 
Approx. 20 mins.
       •  Surgery site assessment. 
       •  Hand photo
Yes, combined with surgery 
aftercare
12 weeks after 
surgery 
Approx. 15 mins.
       •  EQ-5D-5L Questionnaire 
       •  Review of therapy record
Yes, combined with surgery 
aftercare
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Primary outcome: Nodule hardness measured using a tonometer.
Secondary outcomes: Nodule dimensions/area (determined by 
ultrasound imaging), range of motion of the affected digit, grip 
strength, patient reported outcome measures of hand function, pro-
gression to surgery of the digit being assessed, injection experience 
and adverse events.
Tertiary outcomes: Circulating levels of adalimumab, and anti-
bodies to adalimumab. Healthcare resource use and health-related 
quality of life.
Data collection/follow-up summary: Please see Table 5
Sample size: For the early DD RCT, the sample size required is 
138 participants based on detecting a standardised effect size of 
0.62, at 5% significance (2-sided) and 90% power, allowing for a 
20% loss to follow up. The target effect size was determined based 
on a 5 point change in nodule hardness at 12 months and assuming 
a standard deviation of 8. These estimates were based on data from 
a case-control pilot study30. A pilot study of tonometry data from 
25 patients with early DD demonstrated that the palmar tissues of 
patients with untreated early DD were significantly firmer (53±8) 
than the corresponding areas of 12 age and sex matched controls 
(32±3) when measured with a portable Rex Gauge durometer.
Recruitment: Participants will be recruited primarily from outpa-
tient clinics, as well as advertisements in general practices local to 
trial sites and through relevant websites. Potential participants will 
be given/sent the PIL which contains a telephone number and an 
e-mail address to request further information or to make an appoint-
ment for consent and screening to participate in the study.
Potential participants will be contacted within 4 weeks of initial 
contact/expression of interest to arrange telephone screening or an 
invitation for further screening at clinic.
Randomisation: 1:1 adalimumab: placebo, computer generated 
stratified by age (18–49 or ≥50 years) and centre using RRAMP. 
RRAMP is used to randomise participants and this will generate a 
Trial ID and prompt an email to Pharmacy which informs them of 
which investigational medicinal product (IMP) (drug or placebo) 
to dispense. RRAMP also stores the treatment allocation enabling 
emergency unblinding if necessary.
Blinding: Participants and healthcare professionals involved in 
follow-up will be blinded. Those delivering the injection will not 
be blinded, as the 40mg in 0.4ml preparation of adalimumab is now 
only available in a pre-filled syringe.
Participant eligibility criteria for both parts of the trial
All participants will give informed consent before eligibility is 
checked against the criteria listed in Table 6. The person obtaining 
consent will be suitably qualified and experienced, and authorised 
to do so by the Principal Investigator at each site. Participants must 
test negative for HIV, tuberculosis, and hepatitis B and C on sero-
logical testing and a chest X-ray, in accordance with local standard 
procedures for anti-TNF screening. Eligibility criteria are based on 
current clinical use of adalimumab for patients with rheumatoid 
arthritis31 (Table 6).
Trial procedures for both parts of the trial
Participants will be recruited if they meet the inclusion criteria 
and provide written informed consent. All participants will receive 
a PIL. Written consent will be sought following a full verbal and 
Table 4. Table of Early DD RCT objectives and outcome measures.
Objectives Outcome measures
Primary 
Objective
To determine if injection with adalimumab is superior to 
placebo injection of normal saline in controlling disease 
progression. 
Hardness of selected nodule.
Secondary 
Objectives
1. To compare the development of Dupuytren’s nodules 
and associated cord, flexion deformities of the fingers 
and impairment of hand function for participants on each 
treatment. 
 
 
 
 
 
 
2. Monitor for adverse events.
1.1. Ultrasound imaging of nodule size. 
1.2. Range of motion of the affected digit. 
1.3. Grip strength. 
1.4. Participant Reported Outcomes: 
Michigan Hand Outcomes Questionnaire (MHQ) 
Participant identified activity most restricted by 
DD scored on a scale of 1–10. 
1.5. Clinical assessment of the hand. 
 
2.1. Adverse event assessment comparing active 
and placebo groups using visual inspection of 
injection site and laboratory reports. 
2.2. Progression to surgery of the digit being 
assessed.
Tertiary 
Objectives
3. To assess if early DD injection therapy represents good 
value for money compared to current clinical care. 
4. Monitor circulating levels of adalimumab and antibodies 
to adalimumab in the blood
3. Analysis of health care resource utilisation 
data and EQ-5D-5L data to estimate cost and 
utilities from participants on each treatment. 
4. Analysis of blood sample.
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Table 5. Summary of schedule of events for early DD RCT.
What will happen?
Medical check-up 
Approx. 1-2 hours.
Eligibility assessment including chest X-ray and blood tests.
Injection visit 1 
Approx. 2 hours.
       • Dupuytren’s assessment 
       • Blood test 
       • Ultrasound scan 
       • Hand photo 
       • EQ-5D-5L and hand function questionnaires 
       • Resource use questionnaire 
       • Nodule hardness, finger movement and grip strength 
       • Injection and then assessment of injection site
Injection visit 2 
3 months after first injection 
Approx. 2 hours.
       • Assessment of nodules and cords in hand 
       • Blood test 
       • Ultrasound scan 
       • Hand photo 
       • EQ-5D-5L and hand function questionnaires 
       • Resource use questionnaire 
       • Nodule hardness, finger movement and grip strength 
       • Injection and then assessment of injection site
Injection visit 3 and 4 
6 and 9 months later 
Approx. 2 hours.
       • As at 3 months but without blood test
12 months later 
Approx. 1 hour.
       • As at 3 months but without injection
18 months later 
Approx. 1 hour.
       • As at 3 months but without injection or blood test
written explanation of the trial. Participants will personally sign and 
date the current approved version of the Informed Consent Form 
before any trial specific procedures are performed. The person who 
obtained the consent will be suitably qualified and experienced, and 
authorised to do so by the Principal Investigator, at each site. A 
copy of the signed Informed Consent Form will be given to the 
participant.
Screening
Medical history and demographics
Relevant medical history and medications will be recorded, as well 
as demographic data including age, sex, smoking habits and alcohol 
consumption.
Screening tests
To check for eligibility to anti-TNF therapy, blood tests and a chest 
X-ray will be performed. Participants will have a maximum of 20ml 
peripheral blood taken to screen for suitability for anti-TNF therapy 
according to local standard procedures. As a minimum this includes 
screening for Hepatitis B and C and HIV, and testing for latent TB. 
If a recent clear chest X-ray is not present in the patient’s records 
then a chest X-ray will be taken to screen for TB in accordance to 
local standard procedures for anti-TNF screening. If results are pos-
itive for any test, the participant will not be eligible to enter the trial 
and will be informed and counseled about the result of their tests.
Baseline assessments
The maximum amount of time between screening and baseline is 
8 weeks. For participants eligible after review of the results from 
the screening tests, the trial team will verbally check the participant 
is happy to continue to give consent for the trial and record any 
changes to their health since the screening visit.
Baseline assessments include:
•     Ultrasound imaging to assess Dupuytren’s nodule size 
(greyscale).
•     Clinical examination of the hand to establish baseline dis-
ease status, including participant reported disease duration, 
age at onset, occupation, family history of DD, the digits 
involved, configuration of the Dupuytren’s cords, joint 
involvement and whether the flexion deformities are fixed 
or can be passively corrected, presence of Garrod’s knuckle 
pads and Ledderhose’s disease of the feet.
•     Tonometry measurement of the hardness of the palmar tissue 
overlying the Dupuytren’s nodule.
•     A digital photograph of the palm showing the selected 
nodule.
•     Finger range of movement measured using a goniometer.
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Table 6. RIDD trial eligibility criteria.
Inclusion criteria
* Tissue response RCT: DD affecting the fingers resulting in flexion deformities of ≥30° at the 
MCP and/or the PIP joint, with impaired hand function and awaiting surgery 
OR 
Early DD RCT: Participants with early DD nodules shown or reported to progress in the previous 
6 months, with flexion deformities of ≤30° at the metacarpophalangeal and/or at the proximal 
interphalangeal joint, i.e. total flexion deformity of up to 60°
* Nodule distinct and identifiable
* Adequate contraception during the study for women of child bearing potential or their male 
partners
* Aged 18 years or above
* Able and willing to comply with all study requirements
* Willing to allow their general practitioner to be notified of study participation
* Sufficient language fluency for informed consent and to complete questionnaires
Exclusion criteria
* Previous fasciectomy, dermofasciectomy, needle fasciotomy, collagenase injection, steroid 
injection to treat DD in the digit concerned, or previous radiotherapy to the hand concerned
* Pregnant, lactating or planning pregnancy within 5 months after last injection
* Significant renal or hepatic impairment
* Scheduled procedures requiring general anaesthesia during the study, other than planned 
Dupuytren’s surgery (Tissue response RCT only)
* Ever been diagnosed with cancer, is terminally ill or is inappropriate for placebo medication
* Systemic inflammatory disorder such as rheumatoid arthritis or inflammatory bowel disease
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put 
the participants at risk because of participation in the study, or may influence the result of the 
study, or the participant’s ability to participate in the study
* Participated in a study involving an investigational medicinal product in the past 12 weeks
* Known allergy to any anti-TNF agent
* Have HIV or hepatitis B or C. Participants in the Early DD RCT must not be at risk of hepatitis B 
infection
* Known to have an infection or history of repeated infections
* History of Tuberculosis (TB)
* Multiple Sclerosis (MS) or other demyelinating diseases
* History of local injection site reactions
* Needle phobia
* Moderate or severe heart failure
* Being treated with coumarin anticoagulants, such as warfarin (Tissue response RCT only)
* Known lung fibrosis
* Being treated with concomitant biologic DMARDS
* Have received a live vaccine within the previous 4 weeks. Participants may receive concurrent 
vaccinations but must avoid the use of live vaccines for 12 weeks after their last injection
* Received parenteral steroids within the previous 6 weeks
* Participants with known allergy to tetracaine or allergy to either lidocaine or prilocaine will not 
receive Ametop or EMLA cream anaesthetic, respectively 
•     A maximum of 12.5ml peripheral blood taken for assess-
ment, in the central laboratory, of pre-treatment levels of 
adalimumab and antibodies to adalimumab.
•     Participants will complete a Health Quality of Life Ques-
tionnaire, the EQ-5D-5L.
•     The injection will be administered into a single Dupuytren’s 
nodule (see Injection section below). Participants will 
be offered application of Ametop gel or lidocaine/ 
prilocaine cream/EMLA cream 30 minutes to 1 hour prior 
to injection.
•     Injection experience questionnaire
•     Injection site assessment by a trial healthcare professional 
blinded to treatment allocation to monitor for local adverse 
effects
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In addition, for the early DD RCT only:
•     The MHQ hand function questionnaire and identification 
of activity most restricted by DD, scoring it on a scale of 
1–10.
•     Grip strength measured using a JAMAR Dynamometer.
See Supplementary Table 1 for a summary of the schedule for Tis-
sue response RCT and Supplementary Table 2 for the summary of 
schedule for early DD RCT
Intervention
Investigational medicinal product for both parts of the trial
Adalimumab is a human monoclonal antibody that has a Market-
ing Authorisation but will be used off-label for this study. Normal 
saline (0.9% NaCl) will be used as placebo. The safety profile of 
adalimumab is well known, with the most common adverse reac-
tions being mild injection site reactions32.
Where possible, the adalimumab will be supplied in a single use 
glass vial. However, a pre-filled syringe may be the only option if 
using the 40 mg in 0.4 ml formulation.
Procedure for single use glass vials: Participants, treating phy-
sicians and healthcare professionals involved with administering 
the IMP or administering any trial procedure from the injection 
onwards will be blinded to treatment.
The IMP (which will be stored in pharmacy) will be dispensed with 
accountability to a member of the research team who will take the 
IMP to a clinic room separate from the participant. In this sepa-
rate room, a non-blinded member of the research team, who is not 
involved in administering the IMP or assessing the participant, will 
prepare and draw up the adalimumab or normal saline in a syringe 
according to the randomisation, and label the syringes with the par-
ticipant’s ID. The label will not reveal the identity of the IMP. Both 
the IMP and placebo have a similar viscosity and appearance so that 
the two treatments, adalimumab or saline, will be indistinguishable. 
The syringe, without any identifying packaging, will be taken to 
the trial healthcare professional (blinded to treatment allocation) 
to inject the participant. Once adalimumab has been drawn up, it 
tends to lose potency and this precludes preparation of the syringes 
before the participant presents for treatment. There is no stipulated 
time limit. For this trial, no more than 1 hour will elapse before the 
injection is given.
Procedure for pre-filled syringes: Due to the distinctive appear-
ance of the syringe, it is unlikely to be possible to blind the health-
care professional administering the injection to treatment allocation. 
Although this adds extra complication to the IMP administration, 
the benefits of using the new formulation make the efforts to main-
tain blinding worthwhile. The lower volume of the 40mgs in 0.4ml 
pre-filled syringe and removal of the excipient containing citrate 
should result in reduced pain and improved participant acceptabil-
ity33,34. To protect the quality of the data, any person injecting with 
a pre-filled syringe will NOT be involved in administering any fur-
ther trial procedures.
Any healthcare professionals involved with administering any trial 
procedure, including outcome assessments, after the injection of 
IMP will be blinded to treatment.
Participants will be blinded to treatment, using a physical 
screen.
The IMP (which will be stored in pharmacy) will be dispensed with 
accountability to a member of the research team who will take the 
IMP to a clinic room separate from the participant. A non-blinded 
member of the research team will prepare the saline injection for 
the placebo treatment allocation. All syringes (adalimumab or 
saline) will be labelled with the participant’s ID. Care will be taken 
to ensure any healthcare professionals blinded to treatment alloca-
tion are not present for the injection, and the syringe will be hidden 
from the participant’s view. A pre-filled syringe of adalimumab can 
be stored at up to 25°C for up to 14 days, therefore the one hour 
time limit described for glass vials is not applicable with pre-filled 
syringes.
Tissue response RCT: Consented participants will enter the trial 
and receive the injection two weeks prior to the scheduled sur-
gery date. Intra-nodular injections will be delivered into the most 
prominent nodule due to be excised by surgery. If participants 
do not proceed to surgery at 12–18 days following injection, the 
reason will be recorded and they will continue with normal care. 
These participants may be replaced if still during the recruitment 
phase of the tissue response RCT. Participants may withdraw 
from the study and continue normal NHS care. If possible, data 
collected up to the point of withdrawal will be retained, and if 
the participant has received the injection then a safety review of 
the participant medical notes will be undertaken at 3 months from 
randomisation.
Early DD RCT: Consented participants will be screened 
and if eligible, after consent is reaffirmed, they will be randomised 
(1:1) to receive injections of adalimumab (40mg in 0.4ml carrier) 
or saline (placebo 0.4ml) into the active nodule. The participants 
will receive further injections on a maximum of 4 occasions: 
baseline, 3, 6 and 9 months with further follow-up at 12 and 
18 months with no injections. Injections will not be 
administered if the treated nodule decreases in size such that there 
is insufficient nodule tissue to inject. In this case, the participant 
will be encouraged to continue for all intervention visits and 
injections may be reintroduced if the nodule recurs. Injections 
will be discontinued if the participant withdraws from the trial or 
if the investigator considers it necessary for any reason, includ-
ing pregnancy, adverse events, significant protocol deviation or 
non-compliance with study procedures. Compliance will be 
defined as attending not less than 75% of injection visits, 
i.e. 3 visits.
Participants may withdraw from the study and continue normal 
NHS care. If possible, data collected up to the point of withdrawal 
will be retained, and if the participant has received an injection then 
a safety review of the participant medical notes will be undertaken 
for up to 18 months from randomisation.
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Trial outcome measures
Tissue analysis (Tissue response RCT only): The injected nodule 
and surrounding diseased tissue will be removed during scheduled 
surgery approximately two weeks after treatment. The excised nod-
ule tissue will be transported as per instructions specified in the trial 
Sample Handling Manual to the Kennedy Institute laboratories in 
Oxford, where tissue analyses will be undertaken. A scientist not 
involved with the clinical assessment and blinded to treatment allo-
cation will dissect the nodule and extract the mRNA and protein. 
rt-PCR (reverse transcription polymerase chain reaction) will be 
carried out as previously described29. Protein levels will be meas-
ured using electrochemiluminescence (Meso Scale Diagnostics, 
Maryland, USA) or Western blotting (Verjee et al., 2013).
Tissue samples and derivatives will be stored in the Kennedy Institute 
laboratory at the Botnar Research Centre in secure -80°C storage. 
The laboratory has undergone a self-assessment for good clinical 
practice in line with the UKCRC ‘Self-Assessment Questionnaire 
for assessing regulatory compliance in laboratories that perform the 
storage and analysis or evaluation of research samples’35. 
Clinical outcome measures
Nodule hardness (tonometry): Will be measured by a portable 
Rex Gauge durometer RX-1800-00 (Rex Gauge Company Inc. Illi-
nois, U.S.A.)
Grip strength (Early DD RCT only): Grip strength will be meas-
ured using a Jamar meter (CE marked)
Range of motion of the affected digit: Individual range of move-
ment of each joint in the affected digit will be measured using a 
goniometer.
Clinical assessment of the hand: Will assess any changes in the 
injected nodule and adjacent cord.
Nodule size and vascularity: Nodule size and vascularity will be 
assessed by an ultrasound scan with the ultrasound probe placed 
centrally over the nodule. The ultrasound will produce a quantita-
tive result using ImageJ.
Participant reported outcome measures
Injection experience questionnaire: Participants will report on 
the experience of each research injection using an injection ques-
tionnaire which incorporates a numeric rating scale.
Participant identified activity most restricted by DD scored on 
a scale of 1–10 (Early DD RCT only): Participants will be asked 
to identify at baseline the activity most restricted by their DD on 
a scale of 1–10. This activity will be reassessed at all follow-up 
timepoints.
Michigan Hand Outcomes Questionnaire (MHQ) (early DD 
RCT only): The MHQ36 is a hand-specific validated outcome 
measure that, unlike some other instruments, allows the user to 
separately score each hand. It takes approximately 15 minutes to 
complete and comprises six distinct scales that assess overall hand 
function, activities of daily living, pain, work performance, aesthet-
ics, and satisfaction with hand function. The MHQ score ranges 
from 0–100, with higher scores indicating better hand perform-
ance and a higher pain score indicating more pain. The MHQ is 
a validated outcomes measure that has been shown to be sensitive 
to change when used to assess improvement in hand function fol-
lowing surgery for established DD37,38 and was selected following a 
systematic review of outcome measures for DD39.
Health utilities using EQ-5D-5L: The EQ-5D-5L questionnaire is 
a validated preference-based instrument widely used in economic 
evaluation of health care technologies to assess quality of life and 
is the instrument preferred by the National Institute for Health and 
Care Excellence (NICE) to estimate utilities for the calculation of 
quality-adjusted life years (QALYs)40.
Permission has been granted for the use of the MHQ and EQ-5D-5L 
from the relevant agencies.
Resource use questionnaire (early DD RCT only): Participant 
self-reported information on service use will be collected at 3, 6, 9, 
12 and 18 months post randomisation to capture the intensity of use 
of different healthcare services, including primary, community and 
social care. Unit cost data will be obtained from national databases 
such as the BNF and PSSRU Costs of Health and Social Care41. 
Where these are not available the unit cost will be estimated in 
consultation with the lead hospital finance department. In the latter 
process a blanket cost will be applied to the items used to carry out 
the intervention, using a base case provided by the Oxford Univer-
sity Hospital NHS Trust. No additional consent is required for the 
acquisition of these data. Participants will also have the opportunity 
to detail their out of pocket expenditure related to their treatment, as 
well as their ability to return to paid work after treatment.
Safety monitoring
All adverse events (AEs) graded 3 and above according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE) v4.042 
occurring during the trial and up to 12 weeks after surgery (Tissue 
response RCT) or until the end of participation (Early DD RCT) 
that are observed by the Investigator or reported by the participant 
will be recorded on the case report form (CRF), whether or not 
they may be attributed to trial medication. AEs considered related 
to the trial medication as judged by a medically qualified investi-
gator will be followed either until resolution, or until the event is 
considered stable. Serious adverse events (SAEs) will be recorded 
on the trial specific SAE form and reported within 24 hours of the 
Site Study Team becoming aware of the event. Causality will be 
assessed by a medically qualified doctor. The Trial Co-ordinating 
Centre will be responsible for assessing causality and expectedness. 
Any SAEs deemed to be suspected unexpected serious adverse 
reactions (SUSARs) will be reported to the sponsor, the Medicines 
and Healthcare products Regulatory Agency (MHRA) and ethics 
committee within required timelines.
Injection site assessment: The most common adverse reaction 
with adalimumab is injection site reactions (erythema and/or itch-
ing, haemorrhage, pain or swelling). Adverse event assessment will 
involve visual inspection of injection site, surgery site and labora-
tory reports. The injection site will be monitored for adverse events 
using the trial injection site response form. The surgery site and 
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subsequent scar will be monitored using a validated measure for 
wound and scar assessment: POSAS43.
Progression to surgery of the digit being assessed (Early DD 
RCT only): Progression to surgery of the digit being assessed, if 
applicable, will be recorded during the 18 month follow-up.
Monitor blood circulating levels of adalimumab and antibodies 
to adalimumab: 12.5ml of blood will be collected pre- and 
post-injection to measure circulating levels of adalimumab and 
antibodies to adalimumab. Monitoring circulating levels of adali-
mumab will facilitate our understanding of the kinetics of drug 
absorption following intranodular injections and may provide fur-
ther information regarding the optimal frequency of intranodular 
injection.
Data management
A detailed Data Management Plan (DMP) will be followed for the 
management and monitoring of data. All trial data will be entered 
on paper CRFs, sent to the RIDD trial office and entered centrally 
into the trial database. The participants will be identified by a unique 
trial specific number in a database. Participant identifiable informa-
tion will be securely stored in a locked cabinet onsite with restricted 
access, separately from the clinical trial database.
Biological samples
Tissue samples and derivatives will be stored in the Kennedy 
Institute laboratory at the Botnar Research Centre in secure 
-80°C storage. Raw data will be analysed and all data, includ-
ing metadata, will be stored on the University of Oxford servers. 
Summary data will be transferred to the trial database. Full details 
will be recorded in the DMP.
Statistics
A separate statistical analysis plan (SAP) with full details of all 
statistical analyses planned for the data of this study will be drafted 
early in the trial and finalised prior to any primary outcome anal-
ysis. The SAP will be reviewed and will receive input from the 
Trial Steering Committee (TSC) and the Data and Safety Moni-
toring Committee (DSMC). The analysis will be undertaken using 
R, STATA (StataCorp LP), or other well-validated statistical 
packages.
Descriptive statistics will be used to describe the demographics 
between the intervention groups. Continuous outcome measures 
will be presented as a difference in means, together with a 95% 
confidence interval (CI) for each dose cohort (where applicable) 
and overall. Binary and categorical outcomes will be presented as 
numbers and percentages in each category, as well as the difference 
in proportions with the corresponding 95% CI.
The primary outcome for the Tissue Response RCT is expression 
of mRNA for α-SMA, quantified with PCR using the standard 
curve method using three housekeeping genes GAPDH, B2M, and 
PGK1 to normalize the samples. For analysis of the primary and 
key secondary outcomes the placebo results will be pooled across 
cohorts to allow for a dose response to be explored. For the safety 
outcomes, they will be reported within their respective cohorts due 
to the different volumes being used.
For the primary outcome of the early DD RCT, the difference in the 
mean change of nodule hardness between the two groups will be 
reported with 95% confidence intervals. The comparison of change 
in nodule hardness between interventions will be analysed using 
Analysis of Covariance (ANCOVA), adjusting for baseline if it 
is normally distributed. Otherwise, an equivalent non-parametric 
unadjusted test will be used. In order to analyse change in nod-
ule hardness over the full-time period, ANCOVA will be used to 
compare nodule hardness between interventions utilising all time- 
points up to 18 months and adjusting for stratification and other 
important prognostic factors. For all other continuous variables, 
t-tests (or ANCOVA) will be applied if normally distributed to 
compare the intervention with the control group and the differ-
ence in the means, and the corresponding 95% confidence interval 
will be reported. If not normally distributed, non-parametric tech-
niques will be used. For categorical variables, chi-squared tests 
will be used for comparing intervention groups if the variables are 
normally distributed. If a variable is not normally distributed, a 
non-parametric test will be used for the analysis. The level of 
significance to be used is p≤0.05.
The primary statistical analysis will be carried out on the basis of 
intention-to-treat, with all randomised participants included and 
analysed according to their allocated treatment group, irrespective 
of which treatment they actually received. Due to the small sample 
size, missing data will not be imputed for the tissue response RCT. 
For the primary outcome of the early DD RCT, multiple imputation 
using multivariate normal imputation, or other appropriate tech-
niques, will be used to impute missing data if required (full details 
will be specified in the SAP). For the early DD RCT, sensitivity 
analyses will be run on the per protocol population which will be 
defined in the SAP.
Consistency of results will be compared across stratification factors 
using interactions and displayed in Forest plots; however, no formal 
tests will be performed by subgroup.
A decision analytical Markov model combining information on 
costs, quality of life and transition probabilities associated to each 
health state for the first and second year post-treatment will be used 
to estimate the long-term cost-effectiveness of anti-TNF therapy 
compared to current clinical practice in early DD for the Early DD 
RCT.
Trial committees
1. Trial Management Group (TMG)
The TMG will be responsible for day-to-day management of the 
research for the Tissue response RCT and the Early DD RCT. Mem-
bers will include members of the research team, the chief investiga-
tor, trial manager and statistician.
2. Safety Committee (SC) Tissue response RCT
The Safety Committee will include members of the TMG and an 
independent clinician.
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The aims of this committee are to review incoming safety data and 
to make recommendations to the PI regarding dose selection, or to 
the TSC if the safety data indicate the trial should be terminated.
3. Data and Safety Monitoring Committee (DSMC)
The DSMC will review recruitment, study conduct and participant 
safety in the Early DD RCT and will consist of at least two inde-
pendent clinicians and a statistician. This committee will review the 
accumulating data some of which will be analysed separately by 
treatment arm. They will make recommendations to the TSC. The 
terms of reference will be according to a DSMC charter based on 
the DAMOCLES recommendations44.
4. The Trial Steering Committee (TSC)
The TSC will be an independent committee who are ultimately 
responsible for making decisions about the continuation or other-
wise of the trial. The TSC will oversee the whole trial and will have 
the overall responsibility on decisions to continue or stop early. The 
terms of reference will be according to a TSC charter.
Trial organization and administration
The study has received approval from the South Central - Oxford 
B Research Ethics Committee and the MHRA, and will be carried 
out following local legal and regulatory requirements. The trial is 
registered with the European Clinical Trials Database (EudraCT: 
2015-001780-40) and has the Ethics Reference: 15/SC/0259. All 
substantial amendments to the protocol will be submitted to the eth-
ics committee for approval. The study is sponsored by the Univer-
sity of Oxford.
All procedures relating to the trial and personnel involved will be 
carried out in accordance with Medical Research Council Clinical 
Practice, applicable UK legislation and the ethical principles of 
the Declaration of Helsinki. This study protocol follows SPIRIT 
guidelines45. The trial will be reported in line with the CONSORT 
statement46.
Discussion
Dupuytren’s disease is a very common age dependent fibrotic dis-
order of the hand and the number of patients requiring treatment 
in the UK is expected to increase by 50% by 203047. The mainstay 
of treatment remains surgical excision but requires prolonged post-
operative hand therapy, may be associated with a relatively high 
complication rate and is not cost effective48,49. Less invasive proce-
dures such as disruption of the cord with a needle or collagenase 
are associated with rapid recovery of function but have much higher 
recurrence rates50,51. The ideal treatment would prevent the progres-
sion of early nodular disease, before the development of digital 
flexion contractures which lead to impairment of hand function. 
Whilst a number of other treatments, including local steroid injec-
tion and radiotherapy, have been reported, evidence for efficacy 
is lacking and they have not been approved or gained widespread 
acceptance17.
Our laboratory data showed that DD is a localised inflammatory 
disorder29. The nodular tissue comprises mainly myofibroblasts, 
which both secrete and contract the matrix, leading to digital con-
tractures52. Pro-inflammatory cytokines are secreted by the infiltrat-
ing immune cells and we have found that only TNF leads to the 
differentiation of precursor cells into myofibroblasts, and that 
TNF inhibition downregulates the myofibroblast phenotype29. 
These findings form the basis of our current clinical trial, where 
we will recruit participants with early stage DD to receive either 
adalimumab or saline at 3 monthly intervals injected directly into 
the nodules over a 9 month period and followed up for a further 
9 months. The majority of patients with flexion deformities of 
the digits are treated by surgery. This provides the opportunity to 
obtain tissue for analysis following injection of the IMP. Therefore, 
we will recruit individuals scheduled for surgical excision of DD, 
administer adalimumab or placebo two weeks before surgery and 
determine the effect on the myofibroblast phenotype in the surgi-
cally excised tissues. This part of the trial will assess the efficacy 
of different doses of adalimumab at the mRNA and protein level to 
inform the molecular mechanism of action of anti-TNF in DD. The 
myofibroblast is responsible for all forms of fibrosis53 and the data 
from this trial may inform future studies on other fibrotic diseases 
such as frozen shoulder.
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STRONG POINTS
The Authors present a fascinating and plausible attempt to modify this enigmatic disease.
 
The study design is well-developed and appropriate for the matter in question.
 
POINTS TO IMPROVE
There does seem to be some misunderstanding of the difference between a nodule and a cord.
Yet this distinction is essential. Surely the whole purpose of the study is to examine whether one
can prevent a nodule from becoming a cord? This point needs to be fully addressed.
 
In the Introduction and Discussion, there seems to me to have been just a little adornment in the
quest to depict the need for this study: the portrayed risks of progression and complications of
existing treatment, the alleged lack of cost effectiveness of treatment and the suggested need for
prolonged hand therapy.
 
The facts in the introduction should therefore be qualified
 
RCT evidence shows that splintage is not needed after surgery, let alone for 3 to 6 months.
 
The recurrence rate of 10 to 12% is derived from just one small study and is likely to be
inaccurate (due to definition issues). I would suggest the figure is derived from a suitable
review article e.g. Kan  ., 2013 et al
 
Published recurrence data for collagenase are now available at 5 years (Peimer   2015 et al.,
)
 
The complications for surgery and PNF and CCH are not comparable- the high rate of
complications after CCH, although frequent, are transient. This should be emphasised.
 
The Authors may consider mention that eventually, manipulation of genetic pathways rather than
1
2
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 The Authors may consider mention that eventually, manipulation of genetic pathways rather than
biochemical pathways will lead to the solution for this disease
 
The tonometry is described as measuring “the hardness of the palmar tissue overlying the nodule”
(page 8). Surely it measures the hardness of the nodule itself, not the palmar tissue overlying it.
 
The inclusion criteria should include a single digit or palmar disease; otherwise the Michigan score
will not distinguish disability from one or more cords
 
Clarify the “range of motion” measurement. Would this be active or passive?
 
POINTS THAT CANNOT BE IMPROVED
It remains to be shown, but is doubtful, that eradication of a nodule will prevent progression of
disease in a different site- the nodule is probably not the seed from which the cord of DD grows,
but just a localised manifestation of a diffuse tendency. By no means all nodules progress to
symptomatic cords This point is crucial, yet seems glossed over in the introduction wherein the
Authors make a rather enthusiastic pitch to imply that early treatment of nodules will eradicate the
chance of the “risks” of other treatments being required. As a reviewer, I really feel uncomfortable
with allowing this presumption to go unchallenged and insist on suitable justification or dilution.
 
The clinical endpoint- treating nodules of DD before they progress, is laudable but unlikely to be
cost effective. Perhaps 11% of people develop DD nodules. These nodules in their early stage
might cause anxiety but rarely cause symptoms. It is unlikely that any health care system should
view such treatment favourably when comparing the health gains with treating other more
symptomatic or sinister conditions funding for which already challenges existing resources.
 
The Authors aim in Study 2 to recruit patients with “up to 60 degrees”. This represents a substantial
 and does not represent a “ ” nor “early DD”.  A cord of 60 degrees is likely to becord nodule
symptomatic. Unless the proposed treatment removes the cord and thus corrects the deformity,
entry into the trial of a patient with a combined deformity of 60 degrees will deprive the subject of
treatment of a symptomatic condition. I respectfully advise that this inclusion extends beyond the
purpose or capability of the study.
 
The EQ5D questionnaire is worthless in DD as it has no sensitivity to change; it is the wrong
PROM. The Authors have also employed the hand-specific Michigan scale  which is probably more
suitable although I am not quite sure that references 37 and 38 robustly prove that it has been
validated specifically for DD.
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 Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
 I have been a paid advisor on several occasions for SOBI, Pfizer and Actelion whoCompeting Interests:
market the drug Xiapex which is a treatment for Dupuytren’s Disease.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 15 Nov 2017
, University of Oxford, Roosevelt Drive, Oxford, UKCatherine Ball
We would like to thank Professor Isam Atroshi and Professor David Warwick for their supportive
referee reports and helpful comments about our clinical trial protocol. In accordance with their
suggestions, we have made some changes to the protocol text. We have clarified the degree of
digital deformity in early Dupuytren’s disease for inclusion in the RIDD clinical trial. We also have
now stated recurrence rates at 5 years. The technique for obtaining tonometry measurements is
now described in more detail and we have explained how the photographs are used for consistent
placement of the gauge. As requested, further details of the end-user survey concerning
acceptance of injection therapy is now provided. We have also clarified that progression to surgery
is a decision taken independently of the research team. Queries regarding bias and blinding have
been addressed.
 
STRONG POINTS
The Authors present a fascinating and plausible attempt to modify this enigmatic disease.
 
The study design is well-developed and appropriate for the matter in question.
 
POINTS TO IMPROVE
There does seem to be some misunderstanding of the difference between a nodule and a cord.
Yet this distinction is essential. Surely the whole purpose of the study is to examine whether one
can prevent a nodule from becoming a cord? This point needs to be fully addressed.
 
Response:
We appreciate that nodules represent the early stage of disease, with subsequent development of
cords. We will only be recruiting patients with distinct nodules and all injections will be
administered intra-nodularly. Accurate assessment of development or extension of cords is very
difficult and we will be measuring active and passive joint extension in the early disease stage
RCT.
 
In the Introduction and Discussion, there seems to me to have been just a little adornment in the
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In the Introduction and Discussion, there seems to me to have been just a little adornment in the
quest to depict the need for this study: the portrayed risks of progression and complications of
existing treatment, the alleged lack of cost effectiveness of treatment and the suggested need for
prolonged hand therapy. 
The facts in the introduction should therefore be qualified
Response:
Please see above our amendment regarding potential complications of existing treatments. We will
be assessing cost efficacy of adalimumab as part of our study.
 
RCT evidence shows that splintage is not needed after surgery, let alone for 3 to 6 months.
Response:
A recent Cochrane review ‘did not recommend routine use but that splinting should be considered
on an individual basis’. (Rodrigues et al 2015). We agree that the needs of post-operative patients
vary, with some patients requiring splintage but not routinely. This now reads: up to 6 months
 
The recurrence rate of 10 to 12% is derived from just one small study and is likely to be inaccurate
(due to definition issues). I would suggest the figure is derived from a suitable review article e.g.
Kan et al., 2013 1
Response:
Kan 2013 does not report recurrence rates of surgery alone. Recurrence rates from radiotherapy,
fasciectomy, fasciotomy, collagenase injection and other treatments ranged from 2 to 80%. We
quoted the data from a prospective randomised study (van Rijssen 2012), which compared 41
limited fasciectomy patients (125 joints) with 52 PNF patients (167 joints) after 5 years and found
recurrence rates of 21% following limited fasciectomy and 85% following PNF.
Page 3, column 1: We have amended the text to read: However, recurrence rates are high, at 5
years affecting 85% of patients treated with percutaneous needle aponeurotomy   and 47% of
those treated with collagenase   . 
 
 
Published recurrence data for collagenase are now available at 5 years (Peimer et al., 2015)
Response:
Page 3, column 1: We have now cited comparable 5 year data and included the reference by
Peimer et al (2015)
 
The complications for surgery and PNF and CCH are not comparable- the high rate of
complications after CCH, although frequent, are transient. This should be emphasised.
 
 
Response:
Page 3, column 1: This has now been amended to read: over 70%, the majority being minor and
mostly transient
 
The Authors may consider mention that eventually, manipulation of genetic pathways rather than
biochemical pathways will lead to the solution for this disease
Response:
Gene therapy for non-life threatening conditions is some way from the clinic and we consider this to
be outside the remit of our trial protocol.
 
The tonometry is described as measuring “the hardness of the palmar tissue overlying the nodule”
(page 8). Surely it measures the hardness of the nodule itself, not the palmar tissue overlying it.
7
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 (page 8). Surely it measures the hardness of the nodule itself, not the palmar tissue overlying it.
Response:
Page 8, column 2: We have amended this to read “the hardness of the palmar tissue and the
underlying nodule”
 
The inclusion criteria should include a single digit or palmar disease; otherwise the Michigan score
will not distinguish disability from one or more cords
Response:
By limiting recruitment to single digits the population would be very small and difficult to recruit.
 We have included disease specific measures and functional measures.
 
Clarify the “range of motion” measurement. Would this be active or passive?
Response:
Page 8, column 2: This has now been amended to read: Active and passive range of movement.
 
POINTS THAT CANNOT BE IMPROVED
It remains to be shown, but is doubtful, that eradication of a nodule will prevent progression of
disease in a different site- the nodule is probably not the seed from which the cord of DD grows,
but just a localised manifestation of a diffuse tendency. By no means all nodules progress to
symptomatic cords This point is crucial, yet seems glossed over in the introduction wherein the
Authors make a rather enthusiastic pitch to imply that early treatment of nodules will eradicate the
chance of the “risks” of other treatments being required. As a reviewer, I really feel uncomfortable
with allowing this presumption to go unchallenged and insist on suitable justification or dilution.
Response:
Whilst we agree that not all nodules progress to form cords with resultant flexion deformities of the
digits, our published data show that there is an inverse correlation between the presence of
nodules and disease severity (Verjee et al, JHS 2009. 34A: 1785-94).
 
The clinical endpoint- treating nodules of DD before they progress, is laudable but unlikely to be
cost effective. Perhaps 11% of people develop DD nodules. These nodules in their early stage
might cause anxiety but rarely cause symptoms. It is unlikely that any health care system should
view such treatment favourably when comparing the health gains with treating other more
symptomatic or sinister conditions funding for which already challenges existing resources.
This study includes an economic evaluation to identify whether it is cost effective or not.
Response:
There is a clear plan to assess the cost efficacy of adalimumab. Please see tertiary objectives for
the early disease RCT (Table 4)
 
The Authors aim in Study 2 to recruit patients with “up to 60 degrees”. This represents a substantial
cord and does not represent a “nodule” nor “early DD”.  A cord of 60 degrees is likely to be
symptomatic. Unless the proposed treatment removes the cord and thus corrects the deformity,
entry into the trial of a patient with a combined deformity of 60 degrees will deprive the subject of
treatment of a symptomatic condition. I respectfully advise that this inclusion extends beyond the
purpose or capability of the study.
Response:
Whilst we agree that deformity of 60 degrees at a given joint would not be considered early stage
disease, we are referring to up to 30 degrees at the proximal interphalangeal and
metacarpophalangeal joints.
Page 9, Table 6: We have clarified this section to read: Participants with early DD nodules shown
or reported to progress in the previous 6 months, with a flexion deformity of ≤30° at the
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 or reported to progress in the previous 6 months, with a flexion deformity of ≤30° at the
metacarpophalangeal and/or at the proximal interphalangeal joint, i.e. total flexion deformity of up
to 60° for the digit being assessed.
 
Individuals vary as to the level of deformity that they find acceptable and we will only recruit
individuals who do not plan to undergo any elective procedure during the 18 month period of the
trial. However, if the deformity progresses such that the participant and their treating clinicians
decide to proceed with treatment, this will be recorded.
 
The EQ5D questionnaire is worthless in DD as it has no sensitivity to change; it is the wrong
PROM. The Authors have also employed the hand-specific Michigan scale which is probably more
suitable although I am not quite sure that references 37 and 38 robustly prove that it has been
validated specifically for DD.
Response:
There are currently no data available for the EQ-5D-5L in assessing early DD. We are aware that
whilst it may prove not to be sensitive, the EQ-5D-5L is a validated, generalised, health related
quality of life questionnaire recommended by NICE as the accepted measure for conducting a
cost-utility analysis. The EQ-5D instrument facilitates the generation of a utility score from a
person’s health related quality of life.  A utility score refers to the preference that individuals have
for any particular set of health outcomes.  The EQ-5D consists of five health state dimensions
(mobility, self-care, usual activity, pain/discomfort, and anxiety/depression).  There are three levels
of health status to choose from: no problems, some problems, major problems.  Each participant
will value their present health at the date of questionnaire completion.   Participants will also
complete a Visual Analogue Scale which will provide us with a value for the participant’s self-rated
health at the time of survey completion.
Page 11, column 2 has been amended accordingly.
 
There are no published data relating to validation of the Michigan Hand Outcomes Questionnaire
MHQ) in early DD. Reference 37 (Johnston et al 2008) showed that there was a strong correlation
between in MHQ score and change in DD digital fixed flexion deformity. Reference 38 (Herweijer
et al 2007) demonstrated that the MHQ can detect change in patients before and after surgery for
DD. The MHQ has been shown to have high internal consistency which should be useful when
exploring the natural course of DD, where changes occur slowly over time (Shauver and Chung
2013).
 
Is the rationale for, and objectives of, the study clearly described?
Yes
 
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
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This is a well-written trial protocol. The trials address research questions that are important in the
treatment of Dupuytren’s disease (DD).
Introduction:
The statement about the proportions of patients treated with surgery etc in the USA needs a
reference and time frame because this changes over time.
 
Postoperative hand therapy for 3-6 months sounds very long, usually not for the typical patient.
 
To state that collagenase injection treatment has over 70% “complication rate” without specifying
the type of complications is problematic. For people not familiar with collagenase it would sound
that the treatment is not safe when in fact it is a very safe treatment because these “complications”
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 that the treatment is not safe when in fact it is a very safe treatment because these “complications”
are mostly local reactions such as swelling, minor hematomas, pain etc that resolve completely
within days. Applying the same definition of complications to surgery would mean that all patients
have complications.
 
Second paragraph with rationale is very good.
 
There are no details about how the “acceptability of injection therapy” survey was conducted.
Objectives and Methods:
It is not entirely clear what is meant by “control the progression” of early DD.
 
How do we know that nodule hardness is a measure of disease progression in patients with DD
and joint contracture?
 
Are there data about the reliability and validity of measuring “nodule hardness” and size?
 
It would be helpful if a brief description of measuring nodule hardness is provided considering it is
the primary outcome.
 
Are there any data about responsiveness of the EQ-5D-5L in patients with DD?
Early DD RCT:                                  
Definition of “Early” DD: 60 degrees of contracture in a finger is usually not considered early DD. It
could be argued whether this is treatment or prevention of disease progression. Can the active
injection result in partial or complete reduction of the contracture? What does the patient expect
from the treatment?
 
It is unclear whether the total flexion deformity of up to 60 degrees applies to 1 finger or multiple
fingers, for example if a patient had contractures in the small, ring and middle fingers.
 
Primary outcome: at what time point?
 
How will the hand photos be evaluated and will it be done blinded?
 
Is the injection painful (more painful than injecting saline)? Can this influence blinding?
 
Does the injection cause local reaction like swelling, bruising etc, and if so how long do these
changes persist? Can this influence blinding?
 
It is stated that investigators will be able to discontinue participants on the basis of noncompliance
such as not attending some visits; it would be important to avoid introducing risk of bias.
 
How will the possible decision to proceed to surgery during the study be done?
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
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 Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 15 Nov 2017
, University of Oxford, Roosevelt Drive, Oxford, UKCatherine Ball
We would like to thank Professor Isam Atroshi and Professor David Warwick for their supportive
referee reports and helpful comments about our clinical trial protocol. In accordance with their
suggestions, we have made some changes to the protocol text. We have clarified the degree of
digital deformity in early Dupuytren’s disease for inclusion in the RIDD clinical trial. We also have
now stated recurrence rates at 5 years. The technique for obtaining tonometry measurements is
now described in more detail and we have explained how the photographs are used for consistent
placement of the gauge. As requested, further details of the end-user survey concerning
acceptance of injection therapy is now provided. We have also clarified that progression to surgery
is a decision taken independently of the research team. Queries regarding bias and blinding have
been addressed.
 
This is a well-written trial protocol. The trials address research questions that are important in the
treatment of Dupuytren’s disease (DD).
 
Introduction
The statement about the proportions of patients treated with surgery etc in the USA needs a
reference and time frame because this changes over time.
Response:
Page 3, Column 1: Reference now provided: Zhao et al. 2016
 
Postoperative hand therapy for 3-6 months sounds very long, usually not for the typical patient.
Response:
Page 3, Column 1: We agree that the duration of post-operative hand therapy varies, with some
patients requiring more prolonged treatment. This now reads: up to 6 months
 
To state that collagenase injection treatment has over 70% “complication rate” without specifying
the type of complications is problematic. For people not familiar with collagenase it would sound
that the treatment is not safe when in fact it is a very safe treatment because these “complications”
are mostly local reactions such as swelling, minor hematomas, pain etc that resolve completely
within days. Applying the same definition of complications to surgery would mean that all patients
have complications.
Response:
Page 3, Column 1: We have now amended this to read: over 70%, where the majority are relatively
minor and transient, mainly comprising swelling, bruising and pain after collagenase injection.
 
There are no details about how the “acceptability of injection therapy” survey was conducted.
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 There are no details about how the “acceptability of injection therapy” survey was conducted.
Response:
Page 3, Column 2: We now have included further details of the survey and the response rate. We
have amended the text to read: We conducted an end user survey of 46 patients, 24 with early DD
and 22 who had previously undergone surgery. Thirty-three patients (71.7%) responded 62.5%
(n=15) and 82% (n=18) respectively from each group.
 
Objectives and Methods:
It is not entirely clear what is meant by “control the progression” of early DD.
Response:
Table 4, page 7: Progression of early disease is manifest as change in nodule hardness, nodule
size or an increase in finger flexion deformity.  
 
How do we know that nodule hardness is a measure of disease progression in patients with DD
and joint contracture?
and
Are there data about the reliability and validity of measuring “nodule hardness” and size?
Response:
We agree that nodule hardness has not been shown to correlate with joint contracture. Relying on
progression of finger flexion as a measure of disease progression would have resulted in an
unacceptably long follow up period of 3-5 years. We selected nodule hardness as the primary
outcome measure in line with the study by Ketchum et al 2000, who assessed the efficacy of local
steroid injection into the nodule. However, whilst Ketchum et al relied on subjective assessment of
hardness, we will use tonometry to obtain a quantitative measure. We found that tonometry
readings were lower in healthy volunteers compared to people with DD – please refer to the section
on Sample size calculation, page 7. We also referenced a publication by Thurston (1987) who
used tonometry and reported softening of the palm following excision of Dupuytren’s tissue. We
will also use ultrasound scan to assess the size of Dupuytren’s nodules but as there are no
previous data using this modality for Dupuytren’s disease we have chosen this parameter as a
secondary objective. Measurement of surface area of nodules has been shown not to correlate
with disease progression Lanting (2016).
: The injection of nodules of Dupuytren's disease with triamcinoloneKetchum LD, Donahue TK
acetonide.   2000;25(6):1157–62. 11119679 10.1053/jhsu.2000.18493J Hand Surg Am.
 
It would be helpful if a brief description of measuring nodule hardness is provided considering it is
the primary outcome.
Response:
Page 11, Column 1: This section has been amended to read: Tissue hardness will be measured
with a tonometer, ensuring that the gauge is balanced perpendicular to the skin without application
of external pressure by the observer. Five readings will be obtained on each occasion. A
photograph obtained at base line marking the spot to be measured will be used for all subsequent
measurement to ensure consistency of placement of the tonometer. Tonometry has been used to
evaluate skin compliance before and after surgery (Thurston 1987) and reported softening of the
palm following excision of Dupuytren’s tissue.
 
Are there any data about responsiveness of the EQ-5D-5L in patients with DD?
Response:
Page 11, Column 2: The EQ-5D-5L has been used to calculate health state utilities (Gu 2013) in
individuals with more advanced DD. This has now been added the section Health Utilities in
Clinical outcome measures.
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 Clinical outcome measures.
 
Early DD RCT:                                  
Definition of “Early” DD: 60 degrees of contracture in a finger is usually not considered early DD. It
could be argued whether this is treatment or prevention of disease progression. Can the active
injection result in partial or complete reduction of the contracture? What does the patient expect
from the treatment?
Response:
Page 9, Table 6: Whilst we agree that deformity of 60 degrees at a given joint would not be
considered early stage disease, we are referring to up to 30 degrees at the proximal
interphalangeal and metacarpophalangeal joints.
We have clarified this section to read: Participants with early DD nodules shown or reported to
progress in the previous 6 months, with a flexion deformity of ≤30° at the metacarpophalangeal
and/or at the proximal interphalangeal joint, i.e. total flexion deformity of up to 60° for the digit being
assessed.
 
It is unclear whether the total flexion deformity of up to 60 degrees applies to 1 finger or multiple
fingers, for example if a patient had contractures in the small, ring and middle fingers.
Response:
Page 9, Table 6: This refers to a single digital flexion deformity of the digit that we are assessing as
clarified above.
 
Primary outcome: at what time point?
Response:
Page 8: The primary outcome is measured over time as described in Table 5, with the final
measurement being taken at 18 months.
 
How will the hand photos be evaluated and will it be done blinded?
Response:
In the Tissue response RCT the photographs will be used to evaluate healing and quality of
scarring.
Page 11, column 1: In the early DD RCT they will not be evaluated but used to ensure consistent
placement of the tonometer.
 
Is the injection painful (more painful than injecting saline)? Can this influence blinding?
Response:
It is not known whether injection of adalimumab into a nodule is more painful than saline although
when administered subcutaneously there were no significant differences in the pain scores (Furst 
2003). Pain will not influence blinding as each participant will receive the same treatment
(adalimumab or placebo) throughout the course of the study.
 Furst, D.E., et al., Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal
antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis:
results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). The Journal of
Rheumatology, 2003.  (12): p. 2563-2571.30
 
Does the injection cause local reaction like swelling, bruising etc, and if so how long do these
changes persist? Can this influence blinding?
Response:
The participant will be blinded to the treatment received and, as explained above, will receive the
same treatment (adalimumab or placebo) throughout. Therefore, the duration of any local adverse
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 same treatment (adalimumab or placebo) throughout. Therefore, the duration of any local adverse
effects will not influence participant blinding. All assessments will be performed by a blinded
observer before administration of the injection.
 
It is stated that investigators will be able to discontinue participants on the basis of noncompliance
such as not attending some visits; it would be important to avoid introducing risk of bias. 
Response:
Injections will be discontinued if the participant withdraws from the trial or if the investigator
considers it necessary for any reason, including pregnancy, adverse events, significant protocol
deviation or non-compliance with study procedures. Compliance will be defined as attending not
less than 75% of injection visits, i.e. 3 visits. We will endeavour to continue to follow up the
participants with their consent following withdrawal.
 
 
How will the possible decision to proceed to surgery during the study be done?
Response:
The participant will follow the normal clinical pathway. This now reads: Progression to treatment
will be determined by clinicians who are not part of the trial team. 
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it
is of an acceptable scientific standard.
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